Rebordosa, C. ., Plana, E. ., Rubino, A. ., Aguado, J. ., Martinez, D. ., Lei, A. ., … Rivero-Ferrer, E. . (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715–1733. http://doi.org/10.2147/copd.s363997
Administration, Inhalation
Rothnie, K. J., Joksaite, S. ., Sansbury, L. B., Compton, C. ., Di Boscio, V. ., & Ismaila, A. S. (2022). Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 17, 1455–1466. http://doi.org/10.2147/copd.s338436
Sansbury, L. B., Lipson, D. A., Bains, C. ., Anley, G. A., Rothnie, K. J., & Ismaila, A. S. (2022). Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. Int J Chron Obstruct Pulmon Dis, 17, 415–426. http://doi.org/10.2147/copd.s336158
Amegadzie, J. E., Gamble, J. M., Farrell, J. ., & Gao, Z. . (2022). Association between Inhaled β(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis, 17, 1205–1217. http://doi.org/10.2147/copd.s358927
Suissa, S. ., Dell’Aniello, S. ., & Ernst, P. . (2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133–141. http://doi.org/10.1080/15412555.2022.2045265
Suissa, S. ., Dell’Aniello, S. ., & Ernst, P. . (2022). Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd, 19, 109–117. http://doi.org/10.1080/15412555.2022.2035705